This company is no longer active
DP80 Stock Overview
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body’s ability to deliver oxygen. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Diffusion Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.97 |
| 52 Week High | US$15.08 |
| 52 Week Low | US$5.67 |
| Beta | 1.76 |
| 1 Month Change | 31.11% |
| 3 Month Change | 0% |
| 1 Year Change | -47.16% |
| 3 Year Change | -92.47% |
| 5 Year Change | n/a |
| Change since IPO | -76.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| DP80 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 12.7% | -1.7% | -2.8% |
| 1Y | -47.2% | -13.5% | 10.0% |
Return vs Industry: DP80 underperformed the German Biotechs industry which returned -9.3% over the past year.
Return vs Market: DP80 underperformed the German Market which returned 2.1% over the past year.
Price Volatility
| DP80 volatility | |
|---|---|
| DP80 Average Weekly Movement | 7.3% |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: DP80's share price has been volatile over the past 3 months.
Volatility Over Time: DP80's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 13 | Bob Cobuzzi | www.diffusionpharma.com |
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body’s ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.
Diffusion Pharmaceuticals Inc. Fundamentals Summary
| DP80 fundamental statistics | |
|---|---|
| Market cap | €14.24m |
| Earnings (TTM) | -€12.03m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.2x
P/E RatioIs DP80 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DP80 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$13.08m |
| Earnings | -US$13.08m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.41 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did DP80 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/08/18 03:52 |
| End of Day Share Price | 2023/08/16 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Diffusion Pharmaceuticals Inc. is covered by 3 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| David Bautz | Zacks Investment Research Inc. |
| David Bautz | Zacks Small-Cap Research |